Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2011 Jun 23;10(9):1698–1708. doi: 10.1158/1535-7163.MCT-11-0107

Figure 4.

Figure 4

E3330 inhibits NFκB and HIF1 transactivation in stable luciferase-expressing cell lines. A, PaCa-2 cells pGF-NFκB or pGF-mCMV were treated with E3330 for 24-h, followed by TNFα (50ng/mL, 6-h). Green cells indicate induction of NFκB which is blocked by treatment with E3330. B, NFκB activity of cells induced with TNFα, M = media control which shows basal NFκB activity. C, HIF1 activity of cells following E3330 treatment. Firefly luciferase activity was assayed as above and normalized to MTS assay data and then to vehicle control. Experiments were performed in triplicate and repeated at least 3 times in independent experiments. Student’s t tests were performed, and * p < 0.05 level comparing DMSO to E3330.